ReviewFrontiers in medicine2023
Rosacea pathogenesis and therapeutics: current treatments and a look at future targets.
Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Rosacea andMedicina (Kaunas, Lithuania) · 2026Pooled it
- From Genetic Variants to Immune Dysregulation: Multi-Omics Mendelian Randomization Decodes Molecular Networks in Rosacea.Annals of dermatology · 2026Article
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- The Role of Biotics in Rosacea: A Narrative Review.Cureus · 2026Review
- Formulation and Biological Evaluation ofAntioxidants (Basel, Switzerland) · 2026Article
- Neuro-immune-vascular interactions in rosacea and hypertension: a mechanistic review.Frontiers in immunology · 2026Review
- Unraveling the Mechanism of Cuochuangling Pills in Rosacea Treatment: An Integrated Approach Combining Network Pharmacology, Bioinformatics, and Experimental Validation.Clinical, cosmetic and investigational dermatology · 2026Article
- Neurohormonal-Immune Dysregulation in Rosacea: Emerging Perspectives from the Skin-Gut-Brain Axis.Drug design, development and therapy · 2026Review
- Clinical Manifestations and Treatment Outcomes of Pediatric Rosacea Patients: A Retrospective Study.Journal of clinical medicine · 2025Article
- Fully ablative COSkin health and disease · 2025Article
- Casticin reduces rosacea-related inflammation by inhibiting mast cell activation via Mas-related G protein-coupled receptor X2.Inflammopharmacology · 2025Article
- Current Trends and Future Insights on Rosacea Treatment: A Bibliometric Analysis.Clinical, cosmetic and investigational dermatology · 2025Article
- Chemical Composition, Antioxidant, Antibacterial, and Hemolytic Properties of Ylang-Ylang (Pharmaceuticals (Basel, Switzerland) · 2024Article
- Therapy outcomes of IL-17 and JAK inhibitors in rosacea: A systematic review.Journal of biomedical research · 2024Article
- Possible involvement of keratinocyte-derived microvesicle particles in human photosensitivity disorders.Photochemistry and photobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Rosacea is a chronic inflammatory skin condition associated with a significant health and economic burden from costs and loss of productivity due to seeking medical treatment. The disease encompasses multiple phenotypic manifestations involving a complex and multi-variate pathogenesis. Although the pathophysiology of rosacea is not completely understood, ongoing research is continually elucidating its mechanisms. In this review, current concepts of rosacea pathogenesis will be addressed which involve skin barrier and permeability dysfunction, the innate and adaptive immune systems, and the neurovascular system. More specifically, the cathelicidin pathway, transient potential receptor channels, mast cells, and the NLRP3 inflammasome pathway are various targets of current pharmacologic regimens. Future therapies may seek different mechanisms to act on current treatment targets, like the potential use of JAK/STAT inhibitors in ameliorating skin barrier dysfunction or TLR antagonists in alleviating cathelicidin mediated inflammation. Other potential treatments aim for entirely different molecular targets such as microvesicle particle mediated local and systemic inflammation. Ultimately rosacea is associated with a significant health and economic burden which warrants deeper research into its pathogenesis and resultant new treatment discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.